Table 2.
Current and previous multiple sclerosis (MS) treatments of patients with MS in this study
| Patients with MS | Drugs name | Current MS treatments [n (%)] | Previous MS treatments [n (%)] |
|---|---|---|---|
| Immunomodulator group | None | 0 (0) | 32 (74.4) |
| Avonex | 23 (53.5) | 11 (25.6) | |
| Betaferon | 8 (18.6) | 0 (0) | |
| Rebif | 12 (27.9) | 0 (0) | |
| Immunosuppressive group | None | 0 (0) | 0 (0) |
| Avonex | 0 (0) | 4 (9.4) | |
| Betaferon | 0 (0) | 17 (39.5) | |
| Rebif | 0 (0) | 11 (25.6) | |
| Azathioprine | 3 (7.0) | 5 (11.6) | |
| Methotrexate | 1 (2.3) | 1 (2.3) | |
| Cellcept | 19 (44.2) | 0 (0) | |
| Mitoxantrone | 20 (46.5) | 5 (11.6) |
MS: Multiple Sclerosis